• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by TELA Bio Inc.

    4/17/25 4:20:22 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care
    Get the next $TELA alert in real time by email
    DEFA14A 1 tm252403d5_defa14a.htm DEFA14A

     

     

     

    United States
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

     

    xFiled by the Registrant
    ¨Filed by a party other than the Registrant

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement
    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨Definitive Proxy Statement
    xDefinitive Additional Materials
    ¨Soliciting Material under §240.14a-12

     

     

     

    TELA BIO, INC. 

     
    (Name of Registrant as Specified In Its Charter)

     

     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    xNo fee required
    ¨Fee paid previously with preliminary materials
    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

    GRAPHIC

    Step 1: Go to www.envisionreports.com/TELA. Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. www.envisionreports.com/TELA Online Go to www.envisionreports.com/TELA or scan the QR code — login details are located in the shaded bar below. Stockholder Meeting Notice 044BRB Important Notice Regarding the Availability of Proxy Materials for the TELA Bio, Inc. Stockholder Meeting to be Held on May 28, 2025 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2025 proxy statement and Annual Report on Form 10-K for the fiscal year ended December 31, 2024 are available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 16, 2025 to facilitate timely delivery. 2NOT Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. The Sample Company Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares.

    GRAPHIC

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/TELA. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials TELA Bio” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 16, 2025. TELA Bio, Inc., Annual Meeting of Stockholders will be held virtually at https://agm.issuerdirect.com/tela on May 28, 2025 at 10:00 AM Eastern Time. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommend a vote FOR all the nominees listed, FOR Proposals 2, 3, 5, 6 and 7, and 1 YEAR on Proposal 4: 1. Election of Directors: 01 – Jeffrey Blizard 02 – Vince Burgess 03 – Federica O’Brien 2. To ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2025. 3. To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. 4. To approve, on a non-binding, advisory basis, the preferred frequency of future advisory votes on the compensation of the Company’s named executive officers. 5. To approve an amendment to the TELA Bio, Inc. Amended and Restated 2019 Equity Incentive Plan to, among other things, increase the authorized shares issuable thereunder by 3,500,000 shares and eliminate the “evergreen” provision. 6. To approve an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation to limit the liability of certain of our officers as permitted by Delaware law. 7. To approve an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposals 5 and 6. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2025 proxy statement and Annual Report on Form 10-K for the fiscal year ended December 31, 2024 are available to stockholders at www.envisionreports.com/TELA PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. Stockholder Meeting Notice

     

    Get the next $TELA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TELA

    DatePrice TargetRatingAnalyst
    3/21/2025$5.00 → $2.00Overweight → Neutral
    Piper Sandler
    5/31/2022$17.00Buy
    Lake Street
    More analyst ratings

    $TELA
    SEC Filings

    View All

    SEC Form 424B3 filed by TELA Bio Inc.

    424B3 - TELA Bio, Inc. (0001561921) (Filer)

    12/23/25 9:00:37 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by TELA Bio Inc.

    EFFECT - TELA Bio, Inc. (0001561921) (Filer)

    12/19/25 12:15:56 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by TELA Bio Inc.

    S-3 - TELA Bio, Inc. (0001561921) (Filer)

    12/12/25 7:11:07 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 14,250 shares of its common stock to five newly-hired employees, with a grant date of January 20, 2026 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or h

    1/23/26 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 3,600 shares of its common stock to three newly-hired employees, with a grant date of December 9, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or h

    12/12/25 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

    MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler's 37th Annual Healthcare Conference. TELA's management is scheduled to present at Piper Sandler's 37th Annual Healthcare Conference at 2:30 pm ET on December 3rd, 2025. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritiz

    11/19/25 8:30:00 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ew Healthcare Partners Fund 2, L.P. bought $4,000,440 worth of shares (3,604,000 units at $1.11), increasing direct ownership by 88% to 7,714,709 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    11/17/25 4:26:15 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Director Plovanic William J. was granted 11,925 shares (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    11/3/25 4:22:34 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Plovanic William J.

    3 - TELA Bio, Inc. (0001561921) (Issuer)

    11/3/25 4:19:21 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ew Healthcare Partners Fund 2, L.P. bought $4,000,440 worth of shares (3,604,000 units at $1.11), increasing direct ownership by 88% to 7,714,709 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    11/17/25 4:26:15 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    COO and CFO Cuca Roberto bought $144,999 worth of shares (64,444 units at $2.25), increasing direct ownership by 71% to 155,388 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    10/24/24 4:26:40 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Chief Technology Officer Talmo Paul bought $50,000 worth of shares (22,222 units at $2.25), increasing direct ownership by 32% to 91,082 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    10/24/24 4:25:59 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TELA Bio downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded TELA Bio from Overweight to Neutral and set a new price target of $2.00 from $5.00 previously

    3/21/25 8:05:03 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on TELA Bio with a new price target

    Lake Street initiated coverage of TELA Bio with a rating of Buy and set a new price target of $17.00

    5/31/22 9:13:36 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Financials

    Live finance-specific insights

    View All

    TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility

    MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $20.7 million, a 9% increase from the third quarter of 2024Revised full year 2025 revenue guidance of at least 16% growth over full year 2024 Recent Strategic Highlights Strengthened capital position with a credit facility up to $70.0 million debt with Perceptive AdvisorsExpanded Board capabilities with appointments of Betty Jo Rocchio and Bill PlovanicAccelerated hi

    11/13/25 4:01:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio to Announce Third Quarter 2025 Financial Results

    MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2025 financial results on Thursday, November 13, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes befor

    11/4/25 8:30:00 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Reports Second Quarter 2025 Financial Results

    MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Delivered revenue of $20.2 million in the second quarter 2025, representing growth of 26% over the prior year period and sequential growth of 9% over the first quarter of 2025;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the second quarter, resulting in year-over-year revenue increase for each product of approximately 12% and 53%, respectively;Appointed Jeffrey Bliz

    8/11/25 4:03:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

    SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

    11/14/24 1:06:57 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by TELA Bio Inc.

    SC 13G - TELA Bio, Inc. (0001561921) (Subject)

    10/29/24 5:12:40 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

    SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

    10/28/24 4:06:51 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Leadership Updates

    Live Leadership Updates

    View All

    TELA Bio Appoints William Plovanic to Board of Directors

    MALVERN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MALVERN, Pa., November 3, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of William ("Bill") Plovanic, CFA, to its Board of Directors. Mr. Plovanic brings a distinctive combination of capital markets expertise and operational leadership in medical technology. He currently serves as Managing Director, Healthcare Equity Research at Canaccord Genuity. From 2016 to 2021, he held C-level operating and board roles at Obalon Therapeutics, a formerly publicly traded medical device com

    11/3/25 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran

    MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors, and the departure of Lisa Colleran, who has stepped down following five years of service on the Board. Dr. Rocchio is a nationally recognized healthcare leader and one of Modern Healthcare's 50 Most Influential Clinical Executives. She brings decades of experience in advancing clinical excellence, workforce innovation, and supply-chain transformation across some of the nation's l

    10/9/25 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Appoints Jeffrey Blizard as President

    MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio's Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. "This is an important inflection point for TELA Bio," said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. "As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected l

    6/2/25 8:30:00 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care